Hypoxia-activated probiotic agents for breast cancer

用于乳腺癌的缺氧激活益生菌制剂

基本信息

  • 批准号:
    10660233
  • 负责人:
  • 金额:
    $ 38.08万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-05-01 至 2028-04-30
  • 项目状态:
    未结题

项目摘要

ABSTRACT Hypoxia is one of the main features of solid tumors including breast cancer and has been shown to correlate with a poor prognosis. Although many chemotherapeutic agents such as paclitaxel and doxorubicin are significantly effective in a normoxia environment, they are less effective in hypoxic tumor regions due to poor infusion, hypoxia, and acidity. Given its significant impact on treatment and tumor progression, the development of a new approach to specifically target the hypoxic regions of tumors is clinically needed. To address the challenges (unmet medical needs), our objective for this proposal is to develop a new probiotic-assisted approach as bacteria preferentially migrate and accumulate in the hypoxic region of the tumor. We developed our original hypoxia-inducible expression system and have optimized its use in E. coli G3/10 cells, which have been used as a probiotic in humans. We demonstrated that the G3/10 cells preferentially localized the hypoxic regions of xenografted breast tumors in mice. With the new tools of the hypoxia-inducible expression system in G3/10 cells, we will deliver cancer-killing cupredoxin proteins, azurin or rusticyanin, in the hypoxic region of triple-negative breast cancer as they have limited treatment options and a worse prognosis. We hypothesize that the development of a new bacteria-assisted approach to express cancer-killing proteins under the hypoxia-inducible promoter will provide functional tools for specifically targeting hypoxic tumors. To test our hypothesis and improve current therapy, we designed experiments based on our “bi-directional” strategy; a combination of the G3/10-based therapy with standard chemotherapeutic agents (paclitaxel and doxorubicin), so that the chemotherapy suppresses tumors in the outer periphery regions, perfused tumor regions, and our bacterial approach kills tumor in the hypoxic inner regions. Our preliminary data strongly support this concept. Considering the NIH/NCI’s focusing areas in FOA PAR-22-085 (Microbial-based Cancer Imaging and Therapy - Bugs as Drugs), we specifically formed a multidisciplinary team that integrates expertise in basic, translational, and clinical breast cancer biology, microbiology, molecular biology, immunology, pathology, and biostatistics. With the five years of preclinical research proposed in this application, we will discern the value of engineered G3/10 cells as effective bacteria-assisted functional tools. Results from the proposed studies will potentially provide new and effective treatment strategies that specifically target the hypoxic tumor microenvironment.
摘要 缺氧是包括乳腺癌在内的实体瘤的主要特征之一, 与预后不良有关。尽管许多化学治疗剂如紫杉醇和紫杉醇, 多柔比星在常氧环境中显著有效,它们在缺氧肿瘤中不太有效 由于输液不良、缺氧和酸性,鉴于其对治疗和肿瘤的重大影响, 进展,开发一种新的方法,专门针对肿瘤的缺氧区域, 临床需要。为了应对这些挑战(未满足的医疗需求),我们的提案目标是 开发一种新的益生菌辅助方法,因为细菌优先在缺氧环境中迁移和积累, 肿瘤的区域。我们开发了我们最初的缺氧诱导表达系统,并优化了其表达能力。 在E.大肠杆菌G3/10细胞,已被用作人体益生菌。我们证明了G3/10 细胞优先定位于小鼠异种移植乳腺肿瘤的缺氧区域。随着新的工具, 在G3/10细胞中的低氧诱导表达系统,我们将递送杀死癌症的铜氧还蛋白, 天青蛋白或rusticyanin,在三阴性乳腺癌的缺氧区域,因为它们的治疗有限 选择和更差的预后。我们假设开发一种新的细菌辅助方法 在低氧诱导型启动子下表达癌症杀伤蛋白将提供功能工具, 专门针对缺氧肿瘤。为了验证我们的假设并改善目前的治疗,我们设计了 基于我们的“双向”策略的实验;基于G3/10的治疗与标准治疗的组合 化疗剂(紫杉醇和阿霉素),使得化疗抑制肿瘤中的肿瘤。 外周区域,灌注的肿瘤区域,我们的细菌方法在缺氧的内周区域杀死肿瘤。 地区我们的初步数据强烈支持这一概念。考虑到NIH/NCI的重点领域, FOA PAR-22-085(基于微生物的癌症成像和治疗-作为药物的错误),我们专门成立了一个 多学科团队,整合了基础,转化和临床乳腺癌生物学的专业知识, 微生物学、分子生物学、免疫学、病理学和生物统计学。经过五年的临床前研究, 在这项应用中提出的研究中,我们将识别工程化G3/10细胞的价值, 细菌辅助功能工具。拟议研究的结果将可能提供新的和 有效的治疗策略,专门针对缺氧肿瘤微环境。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Tohru Yamada其他文献

Tohru Yamada的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Tohru Yamada', 18)}}的其他基金

Intraoperative Imaging for Lymph Node Metastases
淋巴结转移的术中成像
  • 批准号:
    10646823
  • 财政年份:
    2023
  • 资助金额:
    $ 38.08万
  • 项目类别:
MicroRNA Targeted Therapeutic Approach for Pediatric High-Grade Glioma
MicroRNA 靶向治疗儿童高级别胶质瘤
  • 批准号:
    10043989
  • 财政年份:
    2020
  • 资助金额:
    $ 38.08万
  • 项目类别:
Development of a New Fluorescent Agent for Intraoperative Image-Guided Breast Cancer Surgery
开发用于术中图像引导乳腺癌手术的新型荧光剂
  • 批准号:
    9903292
  • 财政年份:
    2018
  • 资助金额:
    $ 38.08万
  • 项目类别:
Development of a New Fluorescent Agent for Intraoperative Image-Guided Breast Cancer Surgery
开发用于术中图像引导乳腺癌手术的新型荧光剂
  • 批准号:
    10132318
  • 财政年份:
    2018
  • 资助金额:
    $ 38.08万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 38.08万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.08万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 38.08万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.08万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 38.08万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 38.08万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.08万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 38.08万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 38.08万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.08万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了